Pharmacokinetics and pharmacodynamics of mood-altering drugs in patients with cancer

Lovejoy, Nancy C.; Matteis, Margherite

doi:10.1097/00002820-199612000-00001

Cited by 9 publications

(4 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antidepressants are very effective in the treatment of depressive symptoms and are reported to be effective in 70± 80% of the depressed population (Bell 1991;Cathcart et al 1993;Barraclough 1994;Lovejoy & Matteis 1996). The most commonly prescribed drug categories include trycyclic and more recently serotonin reuptake inhibitors (SSRls), the most commonly know ones being Prozac and Zoloft.…”

Section: Antidepressant Medications: a Brief Commentarymentioning

confidence: 99%

Depression in cancer patients: a literature review

Bottomley

1998

European Journal of Cancer Care

151

View full text Add to dashboard Cite

It is estimated that 20-25% of cancer patients suffer often unrecognized and untreated long-term depression, a condition that can make life miserable. Symptoms can include: lack of sleep; loss of interest in life; anxiety; irritation; loss of concentration; and, in severe cases, thoughts of suicide; leading to an overall poor quality of life. Given that the majority of patients diagnosed with clinical depression can be effectively treated with one form of treatment or another (psychological, pharmacological or a combination) it is now important that health care professionals routinely assess and offer treatment for depression in cancer patients. Therefore, this article reviews the literature on depression caused by cancer and highlights practical ways in which health care workers can measure and subsequently treat depression using pharmacological and psychological approaches.

show abstract

Section: Antidepressant Medications: a Brief Commentarymentioning

confidence: 99%

Depression in cancer patients: a literature review

Bottomley

1998

European Journal of Cancer Care

151

View full text Add to dashboard Cite

show abstract

“…Historically, there has been considerable concern regarding addiction and dependence on certain medications but these are both very rare occurrences and are of little relevance in the management of the terminally ill patient. 4 There is also concern regarding polypharmacy in patients with advanced cancer.…”

Section: Introductionmentioning

confidence: 99%

A survey of antidepressant prescribing in the terminally ill

1999

View full text Add to dashboard Cite

Depression is a symptom in a quarter of patients admitted to a palliative care unit, but little is known of how depression in terminally ill patients is treated. We reviewed 1046 consecutive patient admissions, of whom 106 (10%) were prescribed antidepressant medication while under the care of a palliative care team. Of these patients, 21 were prescribed antidepressants when under the care of the home care team, but 80 patients (76%) were started on medication during the final 2 weeks of life. There was consequently insufficient time for the medication to have any therapeutic effect. Seventeen patients were discharged home on antidepressant medication. Three patients were referred for a psychiatric assessment. Patients prescribed antidepressants were significantly younger (P = 0.002) than those who were not. There were no prescriptions for psychostimulants. Although the numbers of patients prescribed antidepressant medication were low in all disease groups, it was notable that patients with breast cancer were prescribed antidepressant medication more frequently than any other patient group. We conclude that there appears to be a need for a coordinated approach to both the assessment and the treatment of depression in terminally ill patients.

show abstract

“…Neuroendocrine-immune modulation (NIM) negative feedback network is one of the important pathophysiological basis of clinical depression in patients with cancer. Depression in pancreatic cancer patients has been linked to the secretion of amines resistant to emotional excitement (7). …”

Section: Introductionmentioning

confidence: 99%

Identifying miRNA‑mRNA regulation network of major depressive disorder in ovarian cancer patients

Zhao

Liu

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Major depression disorder (MDD) has become increasingly common in patients with ovarian cancer, which complicates the treatment course. The microRNA (miRNA)-mRNA regulation network may help elucidate the potential mechanism of MDD in ovarian cancer. The differentially expressed microRNAs (DEmiRs) and mRNAs (DEmRNAs) were therefore identified from the GSE61741, GSE58105 and GSE9116 ovarian cancer datasets using GEO2R. The target genes of the DEmiRs were then obtained using the TargetScan, microRNAorg, microT-CDS, miRDB and miRTarBase prediction tools. The DAVID program was used to identify the KEGG pathways of target genes, and the core genes of major depressive disorder (MDD) were identified using the Kaplan-Meier Plotter for ovarian cancer. A total of 5 DEmiRs (miR-23b-3p, miR-33b-3p, miR-1265, miR-933 and miR-629-5p) were obtained from GSE61741 and GSE58105. The target genes of these DEmiRs were enriched in pathways that were considered high risk for developing MDD in ovarian cancer. A total of 11 risk genes were selected from these pathways as the core genes in the miRNA-mRNA network of MDD in ovarian cancer, and eventually identified the following 12 miRNA-mRNAs pairs: miR-629-5p-FGF1, miR-629-5p-AKT3, miR-629-5p-MAGI2, miR-933-BDNF, miR-933-MEF2A, miR-23b-3p-TJP1, miR-23b-3p-JMJD1, miR-23b-3p-APAF1, miR-23b-3p-CAB39, miR-1265-CDKN1B, miR-33b-3p-CDKN1B, and miR-33b-3p-F2R. These results may provide novel insights into the mechanisms of developing MDD in ovarian cancer patients.

show abstract

Pharmacokinetics and pharmacodynamics of mood-altering drugs in patients with cancer

Cited by 9 publications

References 45 publications

Depression in cancer patients: a literature review

Depression in cancer patients: a literature review

A survey of antidepressant prescribing in the terminally ill

Identifying miRNA‑mRNA regulation network of major depressive disorder in ovarian cancer patients

Contact Info

Product

Resources

About